NCT02535338: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 11 | US | Erlotinib Hydrochloride, CP-358, Cp-358,774, OSI-774, Tarceva, Laboratory Biomarker Analysis, Onalespib Lactate, AT-13387 Lactate, ATI-13387A, ATI-13387AU, Pharmacological Study | National Cancer Institute (NCI) | Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7 | 09/21 | 09/24 | | |
